Low titer maternal antibodies can both enhance and suppress B cell responses to a combined live attenuated human rotavirus and VLP-ISCOM vaccine

We investigated effects of low titer (Lo) circulating MatAb on protection and immunogenicity of attenuated (Att) human rotavirus (HRV) priming and 2/6-virus-like particle (VLP)-immunostimulating complex (ISCOM) boosting (AttHRV/VLP) or VLP-ISCOM alone vaccines. LoMatAb had both enhancing and suppres...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2006-03, Vol.24 (13), p.2302-2316
Main Authors: Nguyen, Trang V., Yuan, Lijuan, P. Azevedo, Marli S., Jeong, Kwang-il, Gonzalez, Ana M., Iosef, Cristiana, Lovgren-Bengtsson, Karin, Morein, Bror, Lewis, Peggy, Saif, Linda J.
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - administration & dosage
Age
Animals
Antibodies, Viral - biosynthesis
Applied microbiology
B cell responses
B-Lymphocytes - immunology
Biological and medical sciences
Clinical trials
Developing countries
Diarrhea
Fundamental and applied biological sciences. Psychology
Gnotobiotic pigs
Hogs
Human rotavirus
Humans
Immune system
Immunity, Maternally-Acquired
Immunogenicity
Immunologic Memory
Immunostimulating complexes
Injections, Intraperitoneal
ISCOM
ISCOMs - administration & dosage
LDCs
Low titer
Maternal antibodies
Membrane filters
Microbiology
Miscellaneous
R&D
Research & development
Rotavirus
Rotavirus Vaccines - immunology
Swine
Vaccine
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Attenuated - immunology
Virion - immunology
Virology
Virus Shedding
Virus-like particles
Viruses
VLP
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated effects of low titer (Lo) circulating MatAb on protection and immunogenicity of attenuated (Att) human rotavirus (HRV) priming and 2/6-virus-like particle (VLP)-immunostimulating complex (ISCOM) boosting (AttHRV/VLP) or VLP-ISCOM alone vaccines. LoMatAb had both enhancing and suppressing effects on B cell responses, depending on tissue, antibody isotype and vaccine. Differential effects of LoMatAb on IgA responses in different tissues suggest that LoMatAb did not suppress induction of IgA effector and memory B cells but impaired homing of these cells to secondary lymphoid or effector tissues, reducing IgA antibody secreting cells and antibodies at these sites. The AttHRV/VLP vaccine partially overcame LoMatAb suppression, conferred moderate protection against virulent HRV (as measured by reduced viral shedding and diarrhea) and represents a new candidate for rotavirus vaccines for both humans and animals.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2005.11.043